SCHEMBL5480404

SCHEMBL5480404

COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC

nearest known ligand 0.97

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.97
FLT1 P17948 7/20 0.97
FLT4 P35916 7/20 0.97
IMPDH2 P12268 11/20 0.74
VCP P55072 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5464876 0.88 FLT1 (0.77) KDRFLT1FLT4IMPDH2VCP
SCHEMBL5477700 0.88 KDR (0.76) KDRFLT1FLT4IMPDH2VCP
SCHEMBL5319878 0.87 FLT1 (0.76) KDRFLT1FLT4IMPDH2VCP
SCHEMBL5469587 0.87 KDR (0.76) KDRFLT1FLT4IMPDH2VCP
Gw627512B SCHEMBL5477421 0.87 KDR (1.00) KDRFLT1FLT4IMPDH2VCP
SCHEMBL1473996 0.86 IMPDH2 (1.00) KDRFLT1FLT4IMPDH2VCP
SCHEMBL1473010 0.83 IMPDH2 (1.00) KDRFLT1FLT4IMPDH2
SCHEMBL5334357 0.83 KDR (0.69) KDRFLT1FLT4IMPDH2VCP
SCHEMBL5480372 0.83 FLT1 (0.69) KDRFLT1FLT4IMPDH2VCP
SCHEMBL5469678 0.82 FLT1 (0.68) KDRFLT1FLT4IMPDH2VCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 US claimed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142437-A1 CHEMICAL COMPOUNDS CDK4, CDK2, CDK3 KDR 33/4885FLT1 56/4885FLT4 47/4885
US-20050288515-A1 Chemical compounds CDK4, CDK2, CDK3 KDR 33/4885FLT1 56/4885FLT4 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.